Net sales increased 143% and significantly improved operating income.
April -
- Net sales:
SEK 8,0 million (3,3). - Operating income:
SEK -2,2 million (-6,4). - Net income for the period:
SEK -2,3 million (-6,8). - Earnings per share:
SEK -0,03 (-0,09), no dilution effects.
-
COVID-19 reorientation support
SEK 0,85 million received.
-
Positive trend and good sales growth in the majority of the company's markets, including record sales to
Spain and 74 percent growth in the company's largest marketGermany .
-
Publication in
The Journal of Heart and Lung Transplantation shows significant benefits from using Glycosorb® ABO intraoperatively for blood group-incompatible heart transplants in children.
-
Good results with the company's UBP product presented at the
Spanish Blood and Transfusion Congress for 2021, SETS.
- Strong end to the quarter and positive signals from the market inspire optimism.
Second quarter | 6 months | Full year | |||
SEK Thousands | Apr- | Apr- | Jan- | Jan- | Jan- |
Net sales | 7, 954 | 3, 267 | 12, 877 | 10, 941 | 27, 000 |
Change in stocks of finished goods | -222 | -786 | -381 | -1, 038 | -81 |
Own work capitalized | 225 | 216 | 416 | 818 | 1, 640 |
Other operating income | 928 | 316 | 1, 031 | 445 | 1, 654 |
Total | 8, 885 | 3, 013 | 13, 943 | 11, 166 | 30, 213 |
Operating expenses | |||||
Raw materials and supplies | -772 | -803 | -1, 199 | -1, 769 | -3, 929 |
Other external expenses | -2, 564 | -2, 111 | -4, 931 | -4, 076 | -9, 284 |
Personnel expenses | -5, 582 | -4, 335 | -10, 955 | -8, 122 | -16, 419 |
Depreciation and amortization of fixed assets | -2, 116 | -1, 983 | -4, 230 | -3, 241 | -7, 830 |
Other operating expenses | -60 | -219 | -124 | -219 | -475 |
Operating income | -2, 209 | -6, 438 | -7, 496 | -6, 261 | -7, 724 |
Net financial items | -124 | -321 | -209 | -165 | -326 |
Income before tax | -2, 333 | -6, 759 | -7, 705 | -6, 426 | -8, 050 |
Taxes | 29 | - | 55 | - | 10 |
Net income | -2, 304 | -6, 759 | -7, 650 | -6, 426 | -8, 040 |
Earnings per share, SEK | -0.03 | -0.09 | -0.1 | -0.09 | -0.11 |
THE COMPLETE INTERIM REPORT FOR THE SECOND QUARTER IS ATTACHED (IN SWEDISH)
This is a translation and an excerpt of the first page of the Swedish version of the Interim report. When in doubt, the Swedish wording prevails.
This disclosure contains information that
Contact
E-mail: info@glycorex.se, phone: 046-286 52 30
Brief information about the company
Glycosorb® ABO is one of
The company has also developed a CE-marked medical device for the development of universal blood plasma and are developing products for the specific reduction of autoantibodies in the treatment of autoimmune diseases, as well as products for specific reduction of galectins. The company also develops products for the simultaneous reduction of blood group A/B specific antibodies and HLA antibodies (tissue-specific antibodies). The company is collaborating with a leading European research institute to develop a product for the treatment of the autoimmune disease rheumatoid arthritis. There are approximately 5 million patients in the EU who have this disease.
https://news.cision.com/glycorex-transplantation/r/glycorex-transplantation-ab--gtab--interim-report-april-june-2021,c3402504
https://mb.cision.com/Main/15286/3402504/1458422.pdf
(c) 2021 Cision. All rights reserved., source